Similar articles

• Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.

  Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y. Naito S, et al. Eur Urol. 2010 Feb;57(2):317-25. doi: 10.1016/j.eururo.2008.12.026. Epub 2009 Jan 3. Eur Urol. 2010. PMID: 19136199
• Comparison of survival rates in patients with metastatic renal cell carcinoma according to treatment era including cytokine and targeted therapy.

  Takagi T, Kondo T, Kennoki T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Takagi T, et al. Jpn J Clin Oncol. 2013 Apr;43(4):439-43. doi: 10.1093/jjco/hys234. Epub 2013 Jan 9. Jpn J Clin Oncol. 2013. PMID: 23303839
• Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.

  Clark PE. Clark PE. Eur Urol. 2009 Jun;55(6):1343-4. doi: 10.1016/j.eururo.2009.01.045. Epub 2009 Jan 30. Eur Urol. 2009. PMID: 19201523 No abstract available.
• Treatment for renal cancer: are we beyond the cytokine era?

  Ramsey S, Aitchison M. Ramsey S, et al. Nat Clin Pract Urol. 2006 Sep;3(9):478-84. doi: 10.1038/ncpuro0581. Nat Clin Pract Urol. 2006. PMID: 16964189 Review.
• Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.

  Wada Y, Takahashi W, Kawano Y, Eto M. Wada Y, et al. Int J Urol. 2012 Apr;19(4):284-95. doi: 10.1111/j.1442-2042.2012.02962.x. Int J Urol. 2012. PMID: 22452375 Review.